Puig L, et al. - A comparative analysis was pursued of the effect of secukinumab and ustekinumab on complete relief from psoriasis-related symptoms, time to health-related quality of life (HRQOL) response, and cumulative benefit among patients with moderate-to-severe plaque psoriasis. In comparison with the ustekinumab treatment, therapy with secukinumab yielded greater and sustained benefits on the patients' lives.